In vivo cytokine production and recombinant interleukin 2 immunotherapy: An insight into the possible mechanisms underlying clinical responses

D. J. Deehan*, S. D. Heys, W. G. Simpson, J. Broom, C. Franks, O. Eremin

*Corresponding author for this work

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Recombinant interleukin 2 (rIL-2), when given to patients with advanced malignant disease, induces a limited beneficial effect, with only 20-30% of patients with solid tumours responding. This present study has identified those patients with advanced colorectal cancer most likely to respond to rIL-2 therapy, by analysis of serum cytokine levels, prior to and during rIL-2 treatment, documented in responders and non-responders. Responders were found to have significantly lower pretreatment serum IL-6 and soluble IL-2 receptor levels (sIL-2R) than non-responders (P < 0.01 and P < 0.05 respectively). During rIL-2 infusion, responders developed high circulating levels of IL-6 and had low constant levels of prostaglandin E2 (PGE2). Non-responders failed to produce IL-6 and demonstrated elevated serum concentrations of PGE2, during infusions of rIL-2. Thus, an enhanced ongoing IL-6 and sIL-2R response, prior to therapy, was detrimental to subsequent treatment with rIL-2. Differential production and/or release of cytokines and prostaglandins, during therapy, further determined the likelihood of response to rIL-2.

Original languageEnglish
Pages (from-to)1130-1135
Number of pages6
JournalBritish Journal of Cancer
Volume69
Issue number6
DOIs
Publication statusPublished - 1 Jun 1994

Fingerprint

Immunotherapy
Interleukin-2
Cytokines
Interleukin-6
Interleukin-2 Receptors
Dinoprostone
Serum
Therapeutics
Prostaglandins
Colorectal Neoplasms
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

In vivo cytokine production and recombinant interleukin 2 immunotherapy : An insight into the possible mechanisms underlying clinical responses. / Deehan, D. J.; Heys, S. D.; Simpson, W. G.; Broom, J.; Franks, C.; Eremin, O.

In: British Journal of Cancer, Vol. 69, No. 6, 01.06.1994, p. 1130-1135.

Research output: Contribution to journalArticle

@article{1221ac8c69fc40cc9f1e82fdf1bba33f,
title = "In vivo cytokine production and recombinant interleukin 2 immunotherapy: An insight into the possible mechanisms underlying clinical responses",
abstract = "Recombinant interleukin 2 (rIL-2), when given to patients with advanced malignant disease, induces a limited beneficial effect, with only 20-30{\%} of patients with solid tumours responding. This present study has identified those patients with advanced colorectal cancer most likely to respond to rIL-2 therapy, by analysis of serum cytokine levels, prior to and during rIL-2 treatment, documented in responders and non-responders. Responders were found to have significantly lower pretreatment serum IL-6 and soluble IL-2 receptor levels (sIL-2R) than non-responders (P < 0.01 and P < 0.05 respectively). During rIL-2 infusion, responders developed high circulating levels of IL-6 and had low constant levels of prostaglandin E2 (PGE2). Non-responders failed to produce IL-6 and demonstrated elevated serum concentrations of PGE2, during infusions of rIL-2. Thus, an enhanced ongoing IL-6 and sIL-2R response, prior to therapy, was detrimental to subsequent treatment with rIL-2. Differential production and/or release of cytokines and prostaglandins, during therapy, further determined the likelihood of response to rIL-2.",
author = "Deehan, {D. J.} and Heys, {S. D.} and Simpson, {W. G.} and J. Broom and C. Franks and O. Eremin",
year = "1994",
month = "6",
day = "1",
doi = "10.1038/bjc.1994.222",
language = "English",
volume = "69",
pages = "1130--1135",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - In vivo cytokine production and recombinant interleukin 2 immunotherapy

T2 - An insight into the possible mechanisms underlying clinical responses

AU - Deehan, D. J.

AU - Heys, S. D.

AU - Simpson, W. G.

AU - Broom, J.

AU - Franks, C.

AU - Eremin, O.

PY - 1994/6/1

Y1 - 1994/6/1

N2 - Recombinant interleukin 2 (rIL-2), when given to patients with advanced malignant disease, induces a limited beneficial effect, with only 20-30% of patients with solid tumours responding. This present study has identified those patients with advanced colorectal cancer most likely to respond to rIL-2 therapy, by analysis of serum cytokine levels, prior to and during rIL-2 treatment, documented in responders and non-responders. Responders were found to have significantly lower pretreatment serum IL-6 and soluble IL-2 receptor levels (sIL-2R) than non-responders (P < 0.01 and P < 0.05 respectively). During rIL-2 infusion, responders developed high circulating levels of IL-6 and had low constant levels of prostaglandin E2 (PGE2). Non-responders failed to produce IL-6 and demonstrated elevated serum concentrations of PGE2, during infusions of rIL-2. Thus, an enhanced ongoing IL-6 and sIL-2R response, prior to therapy, was detrimental to subsequent treatment with rIL-2. Differential production and/or release of cytokines and prostaglandins, during therapy, further determined the likelihood of response to rIL-2.

AB - Recombinant interleukin 2 (rIL-2), when given to patients with advanced malignant disease, induces a limited beneficial effect, with only 20-30% of patients with solid tumours responding. This present study has identified those patients with advanced colorectal cancer most likely to respond to rIL-2 therapy, by analysis of serum cytokine levels, prior to and during rIL-2 treatment, documented in responders and non-responders. Responders were found to have significantly lower pretreatment serum IL-6 and soluble IL-2 receptor levels (sIL-2R) than non-responders (P < 0.01 and P < 0.05 respectively). During rIL-2 infusion, responders developed high circulating levels of IL-6 and had low constant levels of prostaglandin E2 (PGE2). Non-responders failed to produce IL-6 and demonstrated elevated serum concentrations of PGE2, during infusions of rIL-2. Thus, an enhanced ongoing IL-6 and sIL-2R response, prior to therapy, was detrimental to subsequent treatment with rIL-2. Differential production and/or release of cytokines and prostaglandins, during therapy, further determined the likelihood of response to rIL-2.

UR - http://www.scopus.com/inward/record.url?scp=0028216746&partnerID=8YFLogxK

U2 - 10.1038/bjc.1994.222

DO - 10.1038/bjc.1994.222

M3 - Article

C2 - 8198981

AN - SCOPUS:0028216746

VL - 69

SP - 1130

EP - 1135

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 6

ER -